Filter Results

KRIBIOLISA Alemtuzumab (LEMTRADA) ELISA

Quantitative immunoassay for Alemtuzumab. CE Marked. For IVD Use.

SKU: KBI1012

In Stock

  • Details
  • Product Specifications
  • Citations
  • Documents
Introduction:
Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma(CTCL) and T-cell lymphoma under the trade names Campath, MabCampath and Campath-1H, and in the treatment of multiple sclerosis as Lemtrada. It is also used in some conditioning regimens for bone marrow transplantation, kidney transplantation and islet cell transplantation. It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction. MabCampath was withdrawn from the markets in the US and Europe in 2012 to prepare for a higher-priced relaunch of Lemtrada aimed at multiple sclerosis.

Intended Use:
The KRIBIOLISA™ Alemtuzumab ELISA is used as an analytical tool for quantitative determination of Alemtuzumab in serum, plasma and cell culture supernatant.

Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Alemtuzumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Alemtuzumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Alemtuzumab antibody is pipetted and incubated. After washing microwells in order to remove any non-
Suppliers Krishgen Biosystems
Storage Condition 2-8 Deg C
Usage For In-Vitro Diagnostic Use Only

No Data

Enquire

Testimonials

ARE YOU A DISTRIBUTOR

Join KRISHGEN as a verified distributor to get access to over 1 million sku’s, including reagents, biochemicals and assays. Your one stop vendor for life sciences.

Subscribe Newsletter

WE ALSO DISTRIBUTE SPECIFICALLY IN ASIA INCL. INDIA FOR

Krishgen Support